share_log

CbdMD FY24 EPS $(1.79) Up From $(13.32) YoY; Revenue $19.48M Down From $24.16M YoY

CbdMD FY24 EPS $(1.79) Up From $(13.32) YoY; Revenue $19.48M Down From $24.16M YoY

cbdMD 2024财年的每股收益为$(1.79),同比上升自$(13.32); 营业收入为$1948万,同比下降自$2416万
Benzinga ·  2024/12/19 05:13

Financial Highlights from our Fiscal Year 2024:

2024财年的财务亮点:

  • Net sales totaled $19.5 million in fiscal 2024 or a decrease of 19.1% compared to $24.1 million in fiscal 2023.
  • Our gross profit for the year was flat at 62% in fiscal 2024 compared to 62% in fiscal 2023.
  • Our loss from operations was $3.3 million in fiscal 2024 as compared to a loss of $22.4 million in fiscal 2023.
  • Our non-GAAP adjusted EBITDA loss from operations in fiscal 2024 was approximately $1.5 compared to our non-GAAP adjusted EBITDA from operations in fiscal 2023 of approximately $5.5. million, despite the decline in revenue. Our non-GAAP adjusted EBITDA loss for the second half of 2024 was reduced to only $0.2 million from $1.2 million in the prior year comparative period.
  • Net loss attributable to common shareholders for fiscal 2024 was approximately $7.7 million or $1.79 per share as compared to a net loss for fiscal 2023 of approximately $26.9 million, or $13.30 per share. The improvement in fiscal 2024 was principally attributable to ongoing management's efforts on improving profitability, as well as the $13.2 million intangible impairment during 2023.
  • At September 30, 2024, we had working capital of approximately $1.1 million and cash on hand of approximately $2.4 million (which includes $4.7 million of accrued Series A dividend payments) as compared to working capital of approximately $3.4 million and cash on hand of approximately $1.8 million (which includes $0.67 million of accrued Series A dividend payments) at September 30, 2023.
  • We reported direct to consumer (DTC) net sales of $15.7 million or 80.4% of total net sales in fiscal 2024, a decrease of $3.9 million, or 19.9% from fiscal 2023.
  • As of the filing date of our annual report, the majority of our Notes have been converted and the balance of the Notes totaled approximately $0.36 million. When factoring in our cash balance of $2.4 million at the end of September 30, 2024 and ongoing cash consumption rate, management believe the Company has a strong liquidity position going into calendar 2025.
  • 2024财年的净销售额总计为1950万美元,相较于2023财年的2410万美元下降了19.1%。
  • 2024财年的毛利润保持在62%,与2023财年的62%持平。
  • 2024财年的营业亏损为330万美元,而2023财年的营业亏损为2240万美元。
  • 2024财年的非GAAP调整后的EBITDA运营亏损约为1.5百万美元,而2023财年的非GAAP调整后EBITDA运营为约5.5百万美元,尽管收入有所下降。2024年下半年的非GAAP调整后EBITDA亏损减少至仅20万美元,而去年同期为120万美元。
  • 2024财年归属于普通股东的净亏损约为770万美元,或每股1.79美元,相较于2023财年的净亏损约为2690万美元,或每股13.30美元。2024财年的改善主要归因于管理层在提高盈利能力方面的持续努力,以及2023年1320万美元的无形资产减值。
  • 截至2024年9月30日,我们的营运资本约为110万美元,手头现金约为240万美元(其中包括470万美元的应计A系列股息支付),相较于2023年9月30日的营运资本约为340万美元,手头现金约为180万美元(其中包括67万美元的应计A系列股息支付)。
  • 我们报告的直接面向消费者(DTC)净销售额为1570万美元,占2024财年总净销售额的80.4%,比2023财年减少390万美元,降幅为19.9%。
  • 截至我们年度报告的提交日期,绝大多数可转债已经转股,剩余可转债余额约为36万美元。考虑到截至2024年9月30日的现金余额为240万美元和持续的现金消耗率,管理层认为公司在2025年日历年将拥有强大的流动性。

Pursuant to the disclosure requirements of the NYSE American Company Guide Section 610(b), cbdMD is reporting that its audited consolidated financial statements for the fiscal year ended September 30, 2024, included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 18, 2024, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to cbdMD's ability to continue as a going concern. This announcement does not represent any change or amendment to cbdMD's financial statements or to its Annual Report on Form 10-K for the fiscal year ended September 30, 2024.

根据纽交所《美国公司指南》第610(b)节的披露要求,cbdMD报告其截至2024年9月30日的审计合并基本报表已包含在2024年12月18日向证券交易委员会提交的Form 10-k年度报告中,其中包括其独立注册公共会计师事务所的审计意见,涉及cbdMD作为持续经营能力的解释性段落。此公告不代表cbdMD的基本报表或2024年9月30日结束的财年的Form 10-k年度报告的任何变更或修订。

We will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, December 18, 2024, to discuss our September 30, 2024, fourth quarter and full fiscal year financial results and business progress.

我们将在2024年12月18日星期三东部时间下午4:20召开电话会议,讨论截至2024年9月30日的第四季度和整个财年的财务结果及业务进展。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发